Enliven Therapeutics, Inc.
NASDAQEnliven Therapeutics enters its June 9 earnings call in an uncomfortable spot: the stock has shed 16.5% over the past week and 15% over the past month, closing at $35.52, while Wall Street has just sharply lifted its targets — and shorts are quietly adding. The most striking development is the analyst upgrade that arrived as the stock was already sliding. Mizuho's Salim Syed lifted…
Snapshot as of 3 Jun 2026
Enliven Therapeutics enters its June 9 earnings call in an uncomfortable spot: the stock has shed 16.5% over the past week and 15% over the past month, closing at $35.52, while Wall Street has just sharply lifted its…
Enliven Therapeutics heads into its May 11 earnings release carrying the fingerprints of a short-side exodus — but options traders remain more defensively positioned than usual. Short sellers have been quietly exiting.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ELVN — free to start on ORTEX.
Sign up for free →Open ELVN on ORTEX